| Title |
Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial |
| Description |
The study was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial with 108 patients diagnosed with moderate-to-severe SAR. Participants were randomized to receive subcutaneous stapokibart 600 (loading does)-300 mg or placebo every 2 weeks for 4 weeks. The primary endpoint was mean change from baseline in daily reflective total nasal symptom score (rTNSS) over first 2 weeks |
| Organism |
Homo sapiens |
| Data Type |
Expression Profiling |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA034061 |
| Release Date |
2025-03-06 |
| Submitter |
Jingyun Li (18710126583@163.com) |
| Organization |
Beijing Tongren Hospital, Capital Medical University |
| Submission Date |
2024-12-26 |